Tempest Therapeutics, Inc. — Director's Dealing 2013

Jun 11, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2013-06-07

Reporting Person: Lindblom Christopher M (Vice President of Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-06-07	Stock Option (right to buy)	$14.00	A	93846	Acquired	2023-06-07	Common Stock (93846)	Direct

Footnotes

F1: The option vests as to 25% of the shares on June 7, 2014 and vests as to an additional 6.25% of the shares at the end of each successive three-month period thereafter until June 7, 2017.